hrIL-2 active

DRUG3 trials

Sponsors

Peking University People's Hospital

Conditions

Primary Sjögren's SyndromeRheumatoid ArthritisSystemic Lupus Erythematosus

Phase 2

A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus

Peking University People's HospitalSystemic Lupus Erythematosus

Start: 2015-06-30End: 2017-12-31Target: 60Updated: 2015-06-08

A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome

CompletedNCT02464319

Peking University People's HospitalPrimary Sjögren's Syndrome

Start: 2015-06-01End: 2017-08-31Updated: 2018-03-15

Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis

CompletedNCT02467504

Peking University People's HospitalRheumatoid Arthritis

Start: 2015-07-01End: 2017-08-31Updated: 2019-09-09

Related Papers

Metabolic impact of low dose IL-2 therapy for primary Sjögren's Syndrome in a double-blind, randomized clinical trial.

2024-10-316 citations

Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome

JAMA Network Open2022-11-1067 citations

Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial.

2022-03-0748 citations

Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study.

2021-06-1137 citations

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases2019-09-19316 citations